0000899243-21-023011.txt : 20210610
0000899243-21-023011.hdr.sgml : 20210610
20210610174601
ACCESSION NUMBER: 0000899243-21-023011
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210608
FILED AS OF DATE: 20210610
DATE AS OF CHANGE: 20210610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Miller-Rich Nancy
CENTRAL INDEX KEY: 0001735084
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 211009213
MAIL ADDRESS:
STREET 1: C/O INTERCEPT PHARMACEUTICALS, INC.
STREET 2: 10 HUDSON YARDS, 37TH FL
CITY: NEW YORK
STATE: NY
ZIP: 10001
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-761-4904
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-08
0
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0001735084
Miller-Rich Nancy
C/O ALDEYRA THERAPEUTICS, INC.
131 HARTWELL AVENUE
LEXINGTON
MA
02421
1
0
0
0
Stock Option (Right to Buy)
12.97
2021-06-08
4
A
0
13534
0.00
A
2031-06-07
Common Stock
13534
13534
D
Stock Option (Right to Buy)
12.97
2021-06-08
4
A
0
583
0.00
A
2031-06-07
Common Stock
583
583
D
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.
/s/ Nancy Miller-Rich
2021-06-10